WO2021125342A1 - 肥満抑制用組成物 - Google Patents
肥満抑制用組成物 Download PDFInfo
- Publication number
- WO2021125342A1 WO2021125342A1 PCT/JP2020/047516 JP2020047516W WO2021125342A1 WO 2021125342 A1 WO2021125342 A1 WO 2021125342A1 JP 2020047516 W JP2020047516 W JP 2020047516W WO 2021125342 A1 WO2021125342 A1 WO 2021125342A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- prenylflavonoid
- composition according
- fat
- present
- suppression
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 61
- 208000008589 Obesity Diseases 0.000 title claims abstract description 36
- 235000020824 obesity Nutrition 0.000 title claims abstract description 20
- 229930008679 prenylflavonoid Natural products 0.000 claims abstract description 88
- 150000007951 prenylflavonoids Chemical class 0.000 claims abstract description 88
- 239000004480 active ingredient Substances 0.000 claims abstract description 23
- 230000000694 effects Effects 0.000 claims description 31
- 210000000577 adipose tissue Anatomy 0.000 claims description 29
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims description 24
- 210000003205 muscle Anatomy 0.000 claims description 23
- 235000013305 food Nutrition 0.000 claims description 22
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims description 22
- 230000001629 suppression Effects 0.000 claims description 22
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 13
- 102000019280 Pancreatic lipases Human genes 0.000 claims description 13
- 108050006759 Pancreatic lipases Proteins 0.000 claims description 13
- 210000000593 adipose tissue white Anatomy 0.000 claims description 13
- 239000008103 glucose Substances 0.000 claims description 13
- 229940116369 pancreatic lipase Drugs 0.000 claims description 13
- 235000012000 cholesterol Nutrition 0.000 claims description 12
- LPEPZZAVFJPLNZ-SFHVURJKSA-N sophoraflavanone B Chemical compound C1([C@@H]2CC(=O)C=3C(O)=CC(O)=C(C=3O2)CC=C(C)C)=CC=C(O)C=C1 LPEPZZAVFJPLNZ-SFHVURJKSA-N 0.000 claims description 12
- 102000004877 Insulin Human genes 0.000 claims description 11
- 108090001061 Insulin Proteins 0.000 claims description 11
- 229940125396 insulin Drugs 0.000 claims description 11
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 10
- 125000001844 prenyl group Chemical group [H]C([*])([H])C([H])=C(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 10
- 239000008280 blood Substances 0.000 claims description 9
- 210000004369 blood Anatomy 0.000 claims description 9
- 230000002401 inhibitory effect Effects 0.000 claims description 9
- 210000001596 intra-abdominal fat Anatomy 0.000 claims description 9
- 210000000689 upper leg Anatomy 0.000 claims description 8
- YHWNASRGLKJRJJ-UHFFFAOYSA-N sophoraflavanone B Natural products C1C(=O)C2=C(O)C(CC=C(C)C)=C(O)C=C2OC1C1=CC=C(O)C=C1 YHWNASRGLKJRJJ-UHFFFAOYSA-N 0.000 claims description 7
- 210000004003 subcutaneous fat Anatomy 0.000 claims description 7
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 6
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 6
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims description 5
- 230000004584 weight gain Effects 0.000 claims description 5
- 235000019786 weight gain Nutrition 0.000 claims description 5
- 210000000918 epididymis Anatomy 0.000 claims description 3
- 201000010063 epididymitis Diseases 0.000 claims description 3
- 210000003734 kidney Anatomy 0.000 claims description 3
- 210000004185 liver Anatomy 0.000 claims description 3
- 210000000713 mesentery Anatomy 0.000 claims description 3
- 241000124008 Mammalia Species 0.000 description 32
- 239000003925 fat Substances 0.000 description 22
- 230000009471 action Effects 0.000 description 21
- 235000019197 fats Nutrition 0.000 description 21
- 238000000034 method Methods 0.000 description 16
- 235000014113 dietary fatty acids Nutrition 0.000 description 12
- 239000000194 fatty acid Substances 0.000 description 12
- 229930195729 fatty acid Natural products 0.000 description 12
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 11
- 102000004190 Enzymes Human genes 0.000 description 10
- 108090000790 Enzymes Proteins 0.000 description 10
- 201000010099 disease Diseases 0.000 description 10
- 229940088598 enzyme Drugs 0.000 description 10
- 230000037396 body weight Effects 0.000 description 9
- 150000004665 fatty acids Chemical class 0.000 description 9
- 239000000843 powder Substances 0.000 description 9
- 239000000243 solution Substances 0.000 description 9
- 125000004432 carbon atom Chemical group C* 0.000 description 8
- 230000005764 inhibitory process Effects 0.000 description 8
- 238000005303 weighing Methods 0.000 description 8
- 239000003814 drug Substances 0.000 description 7
- YKGCBLWILMDSAV-GOSISDBHSA-N Isoxanthohumol Natural products O(C)c1c2C(=O)C[C@H](c3ccc(O)cc3)Oc2c(C/C=C(\C)/C)c(O)c1 YKGCBLWILMDSAV-GOSISDBHSA-N 0.000 description 6
- 241000699670 Mus sp. Species 0.000 description 6
- 235000019626 lipase activity Nutrition 0.000 description 6
- 238000011282 treatment Methods 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 5
- 229920002472 Starch Polymers 0.000 description 5
- FUSADYLVRMROPL-UHFFFAOYSA-N demethylxanthohumol Natural products CC(C)=CCC1=C(O)C=C(O)C(C(=O)C=CC=2C=CC(O)=CC=2)=C1O FUSADYLVRMROPL-UHFFFAOYSA-N 0.000 description 5
- 230000029142 excretion Effects 0.000 description 5
- 150000002632 lipids Chemical class 0.000 description 5
- 235000021590 normal diet Nutrition 0.000 description 5
- -1 prenyl quercetin Chemical compound 0.000 description 5
- 230000001737 promoting effect Effects 0.000 description 5
- 235000019698 starch Nutrition 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- UVBDKJHYMQEAQV-UHFFFAOYSA-N xanthohumol Natural products OC1=C(CC=C(C)C)C(OC)=CC(OC)=C1C(=O)C=CC1=CC=C(O)C=C1 UVBDKJHYMQEAQV-UHFFFAOYSA-N 0.000 description 5
- ORXQGKIUCDPEAJ-YRNVUSSQSA-N xanthohumol Chemical compound COC1=CC(O)=C(CC=C(C)C)C(O)=C1C(=O)\C=C\C1=CC=C(O)C=C1 ORXQGKIUCDPEAJ-YRNVUSSQSA-N 0.000 description 5
- 235000008209 xanthohumol Nutrition 0.000 description 5
- HSHNITRMYYLLCV-UHFFFAOYSA-N 4-methylumbelliferone Chemical compound C1=C(O)C=CC2=C1OC(=O)C=C2C HSHNITRMYYLLCV-UHFFFAOYSA-N 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 4
- 238000002835 absorbance Methods 0.000 description 4
- 238000010521 absorption reaction Methods 0.000 description 4
- 230000003213 activating effect Effects 0.000 description 4
- 210000003486 adipose tissue brown Anatomy 0.000 description 4
- 210000001035 gastrointestinal tract Anatomy 0.000 description 4
- 239000008187 granular material Substances 0.000 description 4
- 235000009200 high fat diet Nutrition 0.000 description 4
- 229910052500 inorganic mineral Inorganic materials 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 239000011707 mineral Substances 0.000 description 4
- 235000010755 mineral Nutrition 0.000 description 4
- 239000003921 oil Substances 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 230000002265 prevention Effects 0.000 description 4
- 239000002994 raw material Substances 0.000 description 4
- 239000008107 starch Substances 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 239000004375 Dextrin Substances 0.000 description 3
- 229920001353 Dextrin Polymers 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 244000025221 Humulus lupulus Species 0.000 description 3
- 235000008694 Humulus lupulus Nutrition 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
- 240000008042 Zea mays Species 0.000 description 3
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 3
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 3
- 230000001668 ameliorated effect Effects 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 235000005822 corn Nutrition 0.000 description 3
- 235000019425 dextrin Nutrition 0.000 description 3
- 235000005911 diet Nutrition 0.000 description 3
- 230000037213 diet Effects 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 238000000691 measurement method Methods 0.000 description 3
- 239000008267 milk Substances 0.000 description 3
- 210000004080 milk Anatomy 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 235000019198 oils Nutrition 0.000 description 3
- 206010033675 panniculitis Diseases 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 235000000346 sugar Nutrition 0.000 description 3
- 150000008163 sugars Chemical class 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- 229940088594 vitamin Drugs 0.000 description 3
- 229930003231 vitamin Natural products 0.000 description 3
- 235000013343 vitamin Nutrition 0.000 description 3
- 239000011782 vitamin Substances 0.000 description 3
- 210000000636 white adipocyte Anatomy 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical group OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- ZHTTWVRMGWQEOH-UHFFFAOYSA-N 2-(3,4-dihydroxyphenyl)-3,5,7-trihydroxy-8-(3-methylbut-2-enyl)chromen-4-one Chemical compound CC(C)=CCC1=C(O)C=C(O)C(C(C=2O)=O)=C1OC=2C1=CC=C(O)C(O)=C1 ZHTTWVRMGWQEOH-UHFFFAOYSA-N 0.000 description 2
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 2
- YHWNASRGLKJRJJ-KRWDZBQOSA-N 6-prenylnaringenin Chemical compound C1([C@H]2OC3=CC(O)=C(C(=C3C(=O)C2)O)CC=C(C)C)=CC=C(O)C=C1 YHWNASRGLKJRJJ-KRWDZBQOSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical group OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 description 2
- HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 230000036765 blood level Effects 0.000 description 2
- 238000009395 breeding Methods 0.000 description 2
- 230000001488 breeding effect Effects 0.000 description 2
- 235000014121 butter Nutrition 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 235000013339 cereals Nutrition 0.000 description 2
- 238000002591 computed tomography Methods 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 238000006911 enzymatic reaction Methods 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- 235000013373 food additive Nutrition 0.000 description 2
- 239000002778 food additive Substances 0.000 description 2
- 235000021588 free fatty acids Nutrition 0.000 description 2
- 235000015203 fruit juice Nutrition 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 238000003384 imaging method Methods 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 235000013336 milk Nutrition 0.000 description 2
- 229960003512 nicotinic acid Drugs 0.000 description 2
- 235000001968 nicotinic acid Nutrition 0.000 description 2
- 239000011664 nicotinic acid Substances 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 210000000496 pancreas Anatomy 0.000 description 2
- 239000006072 paste Substances 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 230000001766 physiological effect Effects 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 238000010298 pulverizing process Methods 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 229960001285 quercetin Drugs 0.000 description 2
- 235000005875 quercetin Nutrition 0.000 description 2
- REFJWTPEDVJJIY-UHFFFAOYSA-N quercetin Natural products C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 description 2
- 235000020183 skimmed milk Nutrition 0.000 description 2
- 238000003307 slaughter Methods 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- DCXXMTOCNZCJGO-UHFFFAOYSA-N tristearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCC DCXXMTOCNZCJGO-UHFFFAOYSA-N 0.000 description 2
- 235000015112 vegetable and seed oil Nutrition 0.000 description 2
- DRCWOKJLSQUJPZ-DZGCQCFKSA-N (4ar,9as)-n-ethyl-1,4,9,9a-tetrahydrofluoren-4a-amine Chemical compound C1C2=CC=CC=C2[C@]2(NCC)[C@H]1CC=CC2 DRCWOKJLSQUJPZ-DZGCQCFKSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000218235 Cannabaceae Species 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 108010082495 Dietary Plant Proteins Proteins 0.000 description 1
- 208000032928 Dyslipidaemia Diseases 0.000 description 1
- 239000004278 EU approved seasoning Substances 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 208000004930 Fatty Liver Diseases 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- OCIIFJFJVOTFTN-UHFFFAOYSA-N Gancaonin P Chemical compound OC=1C(=O)C2=C(O)C(CC=C(C)C)=C(O)C=C2OC=1C1=CC=C(O)C(O)=C1 OCIIFJFJVOTFTN-UHFFFAOYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 108010068370 Glutens Proteins 0.000 description 1
- 201000005569 Gout Diseases 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 206010019708 Hepatic steatosis Diseases 0.000 description 1
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 1
- 101001008429 Homo sapiens Nucleobindin-2 Proteins 0.000 description 1
- 240000005979 Hordeum vulgare Species 0.000 description 1
- 235000007340 Hordeum vulgare Nutrition 0.000 description 1
- 229920001612 Hydroxyethyl starch Polymers 0.000 description 1
- 201000001431 Hyperuricemia Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 238000012773 Laboratory assay Methods 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 108090001060 Lipase Proteins 0.000 description 1
- 102000004882 Lipase Human genes 0.000 description 1
- 239000004367 Lipase Substances 0.000 description 1
- 208000017170 Lipid metabolism disease Diseases 0.000 description 1
- UPYKUZBSLRQECL-UKMVMLAPSA-N Lycopene Chemical group CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1C(=C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=C)CCCC2(C)C UPYKUZBSLRQECL-UKMVMLAPSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 108010070551 Meat Proteins Proteins 0.000 description 1
- MZSGWZGPESCJAN-MOBFUUNNSA-N Melitric acid A Natural products O([C@@H](C(=O)O)Cc1cc(O)c(O)cc1)C(=O)/C=C/c1cc(O)c(O/C(/C(=O)O)=C/c2cc(O)c(O)cc2)cc1 MZSGWZGPESCJAN-MOBFUUNNSA-N 0.000 description 1
- 229920000881 Modified starch Polymers 0.000 description 1
- 206010028289 Muscle atrophy Diseases 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- 102100027441 Nucleobindin-2 Human genes 0.000 description 1
- 208000004166 Obesity Hypoventilation Syndrome Diseases 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- QGMRQYFBGABWDR-UHFFFAOYSA-M Pentobarbital sodium Chemical compound [Na+].CCCC(C)C1(CC)C(=O)NC(=O)[N-]C1=O QGMRQYFBGABWDR-UHFFFAOYSA-M 0.000 description 1
- 206010035004 Pickwickian syndrome Diseases 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229920001214 Polysorbate 60 Polymers 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 208000002787 Pregnancy Complications Diseases 0.000 description 1
- 235000019484 Rapeseed oil Nutrition 0.000 description 1
- 235000019485 Safflower oil Nutrition 0.000 description 1
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 1
- 108010073771 Soybean Proteins Proteins 0.000 description 1
- 206010041591 Spinal osteoarthritis Diseases 0.000 description 1
- 102000009822 Sterol Regulatory Element Binding Proteins Human genes 0.000 description 1
- 108010020396 Sterol Regulatory Element Binding Proteins Proteins 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 229930003270 Vitamin B Chemical group 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 229930003316 Vitamin D Chemical group 0.000 description 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Chemical group C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 229930003448 Vitamin K Chemical group 0.000 description 1
- KIMDVVKVNNSHGZ-UHFFFAOYSA-N Wighteone Natural products O=C1C2=C(O)C(CC=C(C)C)=C(O)C=C2OC=C1C1=CC=C(O)C=C1 KIMDVVKVNNSHGZ-UHFFFAOYSA-N 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical group OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 239000003674 animal food additive Substances 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 239000012752 auxiliary agent Substances 0.000 description 1
- 239000003899 bactericide agent Substances 0.000 description 1
- 235000013405 beer Nutrition 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 235000019658 bitter taste Nutrition 0.000 description 1
- 238000010241 blood sampling Methods 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- 239000004067 bulking agent Substances 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 150000001746 carotenes Chemical group 0.000 description 1
- 235000005473 carotenes Nutrition 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 206010008118 cerebral infarction Diseases 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 210000000991 chicken egg Anatomy 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 239000003240 coconut oil Substances 0.000 description 1
- 235000019864 coconut oil Nutrition 0.000 description 1
- ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 235000020940 control diet Nutrition 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 229940099112 cornstarch Drugs 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- 238000004042 decolorization Methods 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 235000013325 dietary fiber Nutrition 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 102000038379 digestive enzymes Human genes 0.000 description 1
- 108091007734 digestive enzymes Proteins 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000009547 dual-energy X-ray absorptiometry Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- TUJPOVKMHCLXEL-UHFFFAOYSA-N eriodictyol Natural products C1C(=O)C2=CC(O)=CC(O)=C2OC1C1=CC=C(O)C(O)=C1 TUJPOVKMHCLXEL-UHFFFAOYSA-N 0.000 description 1
- 235000011797 eriodictyol Nutrition 0.000 description 1
- SBHXYTNGIZCORC-UHFFFAOYSA-N eriodyctiol Natural products O1C2=CC(O)=CC(O)=C2C(=O)CC1C1=CC=C(O)C(O)=C1 SBHXYTNGIZCORC-UHFFFAOYSA-N 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 125000004030 farnesyl group Chemical group [H]C([*])([H])C([H])=C(C([H])([H])[H])C([H])([H])C([H])([H])C([H])=C(C([H])([H])[H])C([H])([H])C([H])([H])C([H])=C(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 208000010706 fatty liver disease Diseases 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 235000021001 fermented dairy product Nutrition 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 235000013360 fish flour Nutrition 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 235000011194 food seasoning agent Nutrition 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 235000013376 functional food Nutrition 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 230000014509 gene expression Effects 0.000 description 1
- 125000002350 geranyl group Chemical group [H]C([*])([H])/C([H])=C(C([H])([H])[H])/C([H])([H])C([H])([H])C([H])=C(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000002686 geranylgeranyl group Chemical group [H]C([*])([H])/C([H])=C(C([H])([H])[H])/C([H])([H])C([H])([H])/C([H])=C(C([H])([H])[H])/C([H])([H])C([H])([H])/C([H])=C(C([H])([H])[H])/C([H])([H])C([H])([H])C([H])=C(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 230000004153 glucose metabolism Effects 0.000 description 1
- 235000021312 gluten Nutrition 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 229940050526 hydroxyethylstarch Drugs 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 229960000367 inositol Drugs 0.000 description 1
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 1
- 239000002917 insecticide Substances 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- YKGCBLWILMDSAV-SFHVURJKSA-N isoxanthohumol Chemical compound C1([C@H]2OC=3C(CC=C(C)C)=C(O)C=C(C=3C(=O)C2)OC)=CC=C(O)C=C1 YKGCBLWILMDSAV-SFHVURJKSA-N 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 210000003127 knee Anatomy 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 229940040461 lipase Drugs 0.000 description 1
- 235000019421 lipase Nutrition 0.000 description 1
- 230000002366 lipolytic effect Effects 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 231100000551 menstrual abnormality Toxicity 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 235000020124 milk-based beverage Nutrition 0.000 description 1
- 235000019426 modified starch Nutrition 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 231100000062 no-observed-adverse-effect level Toxicity 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 230000000399 orthopedic effect Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 235000013808 oxidized starch Nutrition 0.000 description 1
- 210000001819 pancreatic juice Anatomy 0.000 description 1
- 229940055726 pantothenic acid Drugs 0.000 description 1
- 235000019161 pantothenic acid Nutrition 0.000 description 1
- 239000011713 pantothenic acid Substances 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- SHUZOJHMOBOZST-UHFFFAOYSA-N phylloquinone Chemical group CC(C)CCCCC(C)CCC(C)CCCC(=CCC1=C(C)C(=O)c2ccccc2C1=O)C SHUZOJHMOBOZST-UHFFFAOYSA-N 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 208000012113 pregnancy disease Diseases 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 235000020991 processed meat Nutrition 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- IKGXIBQEEMLURG-NVPNHPEKSA-N rutin Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 IKGXIBQEEMLURG-NVPNHPEKSA-N 0.000 description 1
- 239000003813 safflower oil Substances 0.000 description 1
- 235000005713 safflower oil Nutrition 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 235000013580 sausages Nutrition 0.000 description 1
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 1
- 239000011669 selenium Substances 0.000 description 1
- 229910052711 selenium Inorganic materials 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- NRHMKIHPTBHXPF-TUJRSCDTSA-M sodium cholate Chemical compound [Na+].C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC([O-])=O)C)[C@@]2(C)[C@@H](O)C1 NRHMKIHPTBHXPF-TUJRSCDTSA-M 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 235000014214 soft drink Nutrition 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 235000019710 soybean protein Nutrition 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 231100000240 steatosis hepatitis Toxicity 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 229960004747 ubidecarenone Drugs 0.000 description 1
- 235000019871 vegetable fat Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- NCYCYZXNIZJOKI-UHFFFAOYSA-N vitamin A aldehyde Chemical group O=CC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C NCYCYZXNIZJOKI-UHFFFAOYSA-N 0.000 description 1
- 235000019156 vitamin B Nutrition 0.000 description 1
- 239000011720 vitamin B Chemical group 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 235000019166 vitamin D Nutrition 0.000 description 1
- 239000011710 vitamin D Chemical group 0.000 description 1
- 150000003710 vitamin D derivatives Chemical group 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 235000019168 vitamin K Nutrition 0.000 description 1
- 239000011712 vitamin K Chemical group 0.000 description 1
- 150000003721 vitamin K derivatives Chemical group 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 229940046008 vitamin d Drugs 0.000 description 1
- 229940046010 vitamin k Drugs 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 235000008939 whole milk Nutrition 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/52—Adding ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/316—Foods, ingredients or supplements having a functional effect on health having an effect on regeneration or building of ligaments or muscles
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/328—Foods, ingredients or supplements having a functional effect on health having effect on glycaemic control and diabetes
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/332—Promoters of weight control and weight loss
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/30—Other Organic compounds
Definitions
- the present disclosure relates to an obesity-suppressing composition containing prenylflavonoid as an active ingredient.
- Hops (Humulus lupulus L.) are perennials of the family Cannabaceae and are dioecious vines.
- the female strain of hops contains a raw material that imparts bitterness to beer, and further contains it as an active ingredient of prenylflavonoids such as isoxanthohumol and 8-prenylnaringenin. It has been reported that these prenylflavonoids have various physiological activities, and are attracting attention as pharmaceuticals and food materials.
- Non-Patent Document 1 8-prenylnaringenin exhibits physiological activities such as estrogen activity
- Patent Document 2 angiogenesis suppression
- Patent Document 3 xanthohumol has been reported to have an effect of suppressing the differentiation of 3T3L1 cells and an effect of suppressing lipid synthesis.
- Non-Patent Document 4 xanthohumol suppresses SREBP activation and lipid synthesis in rats.
- the subject of the present disclosure is at least the provision of a composition for suppressing obesity.
- R 1 to R 9 are independently hydroxyl groups, hydrogen atoms or prenyl groups
- R 10 represents a hydroxyl group or hydrogen atom
- one or more of R 1 to R 9 is a prenyl group. Is.
- [2] The composition according to [1], wherein the prenylflavonoid is 8-prenylnaringenin.
- the obesity suppression is a weight gain suppression or a body fat increase suppression.
- [4] The composition according to any one of [1] to [3], wherein the obesity suppression is suppression of visceral fat increase or suppression of subcutaneous fat increase.
- [5] The composition according to any one of [1] to [4], wherein the obesity suppression is suppression of an increase in visceral fat in the liver, mesentery, perrenal kidney or epididymis.
- [6] The composition according to any one of [1] to [5], which is used for suppressing the increase of white fat.
- [7] The composition according to any one of [1] to [6], which is used for inhibiting the activity of pancreatic lipase.
- [8] The composition according to any one of [1] to [7], which is used for suppressing an increase in blood concentration of glucose, cholesterol, or insulin.
- This disclosure can at least have the effect of providing technology for controlling obesity.
- the graph which shows the result of Example 1 which is one Embodiment. The graph which shows the result of Example 1 which is one Embodiment.
- the graph which shows the result of Example 1 which is one Embodiment. The graph which shows the result of Example 1 which is one Embodiment.
- the graph which shows the result of Example 1 which is one Embodiment. The graph which shows the result of Example 1 which is one Embodiment.
- the graph which shows the result of Example 2 which is one Embodiment. The graph which shows the result of Example 2 which is one Embodiment.
- One embodiment is an obesity-suppressing composition containing prenylflavonoid represented by the following general formula (1) as an active ingredient.
- the prenylflavonoid is sometimes referred to as "prenylflavonoid”.
- R 1 to R 9 are independently hydroxyl groups, hydrogen atoms or prenyl groups
- R 10 represents a hydroxyl group or hydrogen atom
- one or more of R 1 to R 9 is a prenyl group. Is.
- prenylflavonoid represented by the above general formula (1) may be referred to as “prenylflavonoid of the present embodiment”.
- the composition for obesity suppression containing prenylflavonoid represented by the above general formula (1) as an active ingredient may be described as "the composition of the present embodiment".
- the composition of the present embodiment may contain only the prenylflavonoids of the present embodiment, but may be a mixture with other components, in which case the components may be uniform or non-uniform. Good.
- Mammals that ingest the composition of this embodiment or receive the composition of this embodiment include humans and mammals other than humans. Examples of mammals other than humans include rats, mice, dogs, cats, monkeys, pigs, and cows.
- prenylflavonoids of the present embodiment include flavonoids having a prenyl group such as prenylnaringenin, isoxanthofumole, prenylkercetin, prenyleriodictyol, and prenylgenistine.
- the prenyl group may have 1 or more.
- Examples of the prenyl group include a dimethylallyl group (5 carbon atoms), a geranyl group (10 carbon atoms), a farnesyl group (15 carbon atoms), a geranylgeranyl group (20 carbon atoms), a geranylfarnesyl group (25 carbon atoms), and a hexaprenyl group. (30 carbon atoms), octaprenyl group (40 carbon atoms), decaprenyl group (50 carbon atoms).
- prenylnaringenin examples include 8-prenylnaringenin and 6-prenylnaringenin.
- prenyl quercetin examples include 8-prenyl quercetin, 6-prenyl quercetin, and 5'-prenyl quercetin.
- prenyl eriodictyol examples include Nimfeol A, Nimfeol B, Nimfeol C, and Isonimfeol C.
- prenylgenistein examples include 6-prenylgenistein.
- Xanthohumol does not have the structure represented by the above general formula (1).
- the method for obtaining the prenylflavonoid of the present embodiment is not particularly limited, and a commercially available product may be used, it may be obtained by synthesizing it by chemical synthesis, or it may be obtained by producing it in a microorganism.
- the obtained prenylflavonoid of the present embodiment can be used as it is, but it may be dried and powdered. Further, if necessary, the obtained prenylflavonoid of the present embodiment may be subjected to purification, concentration treatment or the like.
- purification treatment treatments such as filtration or adsorption and decolorization using an ion exchange resin or an activated carbon column can be performed.
- a conventional method such as an evaporator can be used for the concentration treatment.
- a method of pulverizing the obtained prenylflavonoid (or a purified or concentrated product thereof) of the present embodiment by freeze-drying, and adding excipients such as dextrin, cornstarch, gum arabic and the like and spraying. It may be pulverized according to a known method such as a method of pulverizing by dry treatment. After that, if necessary, it may be dissolved in pure water, ethanol or the like for use.
- prenylflavonoid of this embodiment with respect to the total amount of the composition of this embodiment is not particularly limited as long as the action / effect of prenylflavonoid of this embodiment is exhibited, but as the total amount of prenylflavonoid of this embodiment, In one preferred embodiment of the present embodiment, it is 0.00001% by mass or more, in another preferred embodiment, it is 0.00005% by mass or more, and in yet another preferable aspect, it is 0.0001% by mass or more. In one preferred embodiment of the present embodiment, it is 5% by mass or less, in another preferred embodiment, it is 0.5% by mass or less, and in yet another preferable aspect, it is 0.05% by mass or less.
- the effective intake or effective dose of the composition of the present embodiment is appropriately set depending on the age, body weight, disease, etc., administration route, administration schedule, formulation form, etc. of the subject, and the mammal is allowed to ingest or administer it. By doing so, there is no particular limitation as long as the action / effect of prenylflavonoid of the present embodiment is exhibited in the mammal.
- the total amount of prenylflavonoids in this embodiment is 0.01 mg or more per day and kg body weight in one preferred embodiment of the present embodiment, 0.05 mg or more in another preferred embodiment, and yet another preferred one.
- composition of the present embodiment may be ingested or administered once a day, or may be ingested or administered in a plurality of times a day. In addition, it may be ingested or administered once every few days or weeks.
- Obsity suppression includes suppression of weight gain or suppression of body fat gain.
- the weight of the mammal when the mammal ingests or is administered prenylflavonoid of the present embodiment is higher than when the mammal does not ingest or is not administered. To make it smaller or to make it equivalent. Body weight can be measured, for example, on a scale.
- the obesity-suppressing action in the present specification is a body fat increase-suppressing action
- the mammal ingests or administers prenylflavonoid of the present embodiment it is more likely that the mammal ingests or does not ingest it. It means to reduce or equalize body fat.
- Body fat can be measured, for example, by weighing adipose tissue removed from the body, measuring the body fat percentage by the impedance method, measuring the fat area after CT scan imaging, and the like.
- the body fat includes visceral fat or subcutaneous fat.
- visceral fat can also be measured by, for example, removing adipose tissue adhering to each organ in the body, weighing it, and measuring the total amount thereof.
- subcutaneous fat can also be measured, for example, by weighing the adipose tissue removed from the subfural tissue.
- the visceral fat also includes visceral fat in the liver, mesentery, perrenal kidney or epididymis.
- any visceral fat can also be measured by, for example, removing and weighing the adipose tissue deposited around the tissue.
- the prenylflavonoids of this embodiment can be used for the following purposes.
- the composition of this embodiment contains prenylflavonoid of this embodiment as an active ingredient, the composition of this embodiment can also be used for the following uses.
- the prenylflavonoid of the present embodiment has an effect of suppressing the increase of white fat, it can be used for the purpose of suppressing the increase of white fat. From this, it is possible to provide a composition for suppressing an increase in white fat, which comprises the prenylflavonoid of the present embodiment as an active ingredient. Further, in the present specification, it is possible to provide a composition for suppressing obesity used for suppressing an increase in white fat, which contains prenylflavonoid of the present embodiment as an active ingredient.
- the effect of suppressing the increase in white fat means that when a mammal ingests or receives prenylflavonoid of the present embodiment, the amount of white fat in the mammal is reduced as compared with the case where it is not ingested or not administered. It means to make it in the same state.
- White adipose tissue can be measured, for example, by weighing the white adipose tissue removed from the body, measuring by the impedance method, measuring the fat area after CT scan imaging, and the like.
- a white adipocyte differentiation marker expressed in white adipocytes can be measured by measuring with Western blotting. Examples of the white adipocytes include cells derived from mouse fibroblast 3T3-L1.
- the prenylflavonoid of the present embodiment has an action of inhibiting the activity of pancreatic lipase, it can be used for the purpose of inhibiting the activity of pancreatic lipase.
- Mammalian pancreatic lipase is a digestive enzyme that is synthesized in the pancreas and secreted into pancreatic juice to hydrolyze triacylglycerol. From this, it is possible to provide a composition for inhibiting pancreatic lipase activity, which comprises the prenylflavonoid of the present embodiment as an active ingredient.
- the present specification can provide an obesity-suppressing composition used for inhibiting the activity of pancreatic lipase, which comprises the prenylflavonoid of the present embodiment as an active ingredient.
- the activity-inhibiting action of pancreatic lipase means that when a mammal ingests or receives prenylflavonoid of the present embodiment, the activity inhibition of pancreatic lipase of the mammal is greater than when it is not ingested or not administered.
- the degree of activity inhibition of pancreatic lipase can be evaluated in an in vitro system, for example, by the activity inhibition rate, and the activity inhibition rate can be calculated, for example, as in Examples described later.
- the action of hydrolyzing the ester bond of triacylglycerol and inhibiting or suppressing the activity of an enzyme having an action of decomposing into fatty acid and glycerin can be evaluated.
- an enzyme having an action of decomposing into fatty acid and glycerin For example, 4-methylumbelliferone. It can be measured by using a fatty acid ester as a substrate, allowing lipase derived from porcine pancreas to act, and quantifying 4-methylumbelliferone released after the enzymatic reaction by a fluorescence measurement method.
- the fat ingested by the diet is decomposed into fatty acids and glycerin by the action of this lipolytic enzyme, pancreatic lipase, and then absorbed from the epithelial cells of the small intestine.
- pancreatic lipase When the activity of pancreatic lipase is inhibited, fat absorption in the intestinal tract is suppressed. Therefore, the prenylflavonoid of the present embodiment can be used for the purpose of suppressing fat absorption in the intestinal tract. From this, it is possible to provide a composition for suppressing fat absorption in the intestinal tract, which comprises the prenylflavonoid of the present embodiment as an active ingredient.
- the present specification can provide an obesity-suppressing composition used for suppressing fat absorption in the intestinal tract, which comprises the prenylflavonoid of the present embodiment as an active ingredient.
- the prenylflavonoid of the present embodiment has an effect of suppressing an increase in the blood concentration of glucose, cholesterol or insulin, it can be used for an application of suppressing an increase in the blood concentration of glucose, cholesterol or insulin. From this, it is possible to provide a composition for suppressing an increase in blood concentration of glucose, cholesterol, or insulin containing prenylflavonoid of the present embodiment as an active ingredient.
- the present specification can provide an obesity-suppressing composition used for suppressing an increase in blood concentration of glucose, cholesterol, or insulin, which contains prenylflavonoid of the present embodiment as an active ingredient.
- the inhibitory effect on the increase in blood concentration of glucose, cholesterol, or insulin means that when a mammal ingests or receives prenylflavonoid of the present embodiment, the glucose of the mammal is more than when it is not ingested or not administered. , Cholesterol, or insulin to reduce blood levels or to achieve equivalent levels. Any blood concentration can be measured using, for example, a commercially available measuring kit.
- the prenylflavonoid of the present embodiment has an action of increasing muscle weight, it can be used for the purpose of increasing muscle weight. From this, it is possible to provide a composition for increasing muscle weight, which comprises the prenylflavonoid of the present embodiment as an active ingredient.
- the present specification can provide an obesity-suppressing composition used for increasing muscle weight, which comprises the prenylflavonoid of the present embodiment as an active ingredient.
- the effect of increasing muscle weight means that when a mammal ingests or receives prenylflavonoid of the present embodiment, the muscle weight of the mammal is larger than when it is not ingested or not administered.
- the muscle weight can be measured, for example, by body composition analysis measurement or the Dual Energy X-ray Absorptiometry (DXA) method, or by weighing the muscle with a balance after removing the muscle from the body.
- the thigh muscle can be exemplified as the muscle.
- the weight of the thigh muscle can be measured, for example, by removing it from the body and then weighing it with a balance or the like.
- the prenylflavonoid of the present embodiment has an action of promoting the excretion of body fat to the outside of the body, it can be used for the purpose of promoting the excretion of body fat to the outside of the body. From this, it is possible to provide a composition for promoting the excretion of body fat to the outside of the body, which comprises the prenylflavonoid of the present embodiment as an active ingredient. Further, in the present specification, it is possible to provide an obesity-suppressing composition used for promoting the excretion of body fat to the outside of the body, which contains prenylflavonoid of the present embodiment as an active ingredient.
- the action of promoting the excretion of body fat to the outside of the body means that when the mammal ingests or receives prenylflavonoid of the present embodiment, it is excreted from the body of the mammal more than when it is not ingested or not administered. It means that the amount of body fat is large.
- the amount of body fat excreted from the body can be measured, for example, by extracting the lipid excreted in feces using the Folch method and weighing it.
- the prenylflavonoid of the present embodiment has an action of activating ⁇ -oxidase of fatty acid, it can be used for activation of ⁇ -oxidation enzyme of fatty acid. From this, it is possible to provide a composition for activating ⁇ -oxidizing enzyme of fatty acid containing prenylflavonoid of this embodiment as an active ingredient. Further, in the present specification, it is possible to provide an obesity-suppressing composition used for activating ⁇ -oxidizing enzyme of fatty acid, which contains prenylflavonoid of the present embodiment as an active ingredient.
- the action of activating ⁇ -oxidase of fatty acid means that when a mammal ingests or administers prenylflavonoid of the present embodiment, the activity of ⁇ -oxidase of fatty acid is higher than when it is not ingested or not administered.
- the activity of ⁇ -oxidizing enzyme of fatty acid can be measured, for example, by measuring the amount of ⁇ -oxidizing enzyme mRNA and confirming the gene expression level.
- Preferred embodiments of the composition of this embodiment include pharmaceuticals, foods and drinks (including supplements), feeds, and the like. That is, some preferred embodiments that can be provided by the present disclosure include an obesity-suppressing drug containing the prenylflavonoids of the present embodiment, and obesity-suppressing foods and drinks (including supplements) containing the prenylflavonoids of the present embodiment. ), And a prenylflavonoid-containing feed for controlling obesity.
- the prenylflavonoid of the present embodiment is used as a pharmaceutical material
- either oral administration or parenteral administration can be adopted as the method of application as a pharmaceutical.
- the active ingredient can be mixed with a solid or liquid NOAEL suitable for administration methods such as oral administration, rectal administration, and injection, and administered in the form of a conventional pharmaceutical preparation.
- a preparation include solid preparations such as tablets, granules, powders and capsules, liquid preparations such as solutions, suspensions and emulsions, and lyophilized preparations. It can be prepared by conventional means.
- Examples of the above-mentioned pharmaceutical non-toxic carrier include glucose, lactose, sucrose, starch, mannitol, dextrin, fatty acid glyceride, polyethylene glycol, hydroxyethyl starch, ethylene glycol, polyoxyethylene sorbitan fatty acid ester, amino acid, gelatin, and the like.
- Examples include albumin, water, and physiological saline.
- conventional additives such as stabilizers, wetting agents, emulsifiers, binders, and tonicity agents can be added as appropriate.
- the above-mentioned medicine can be used for the prevention or amelioration of diseases, disorders, symptoms and symptoms (which may be referred to as "disease and the like" in the present specification) which can be prevented or ameliorated by the prenylflavonoids of the present embodiment.
- Disease and the like which can be referred to as "disease and the like” in the present specification
- prenylflavonoids of the present embodiment ..
- “Improvement” includes "treatment”.
- the diseases include obesity, diabetes, abnormal glucose metabolism kidney disease, hypertension, and myocardial infarction, which are listed as related diseases to obesity by the Japan Obesity Prevention Association.
- Angina coronary artery disease
- cerebral infarction gout
- hyperuricemia dyslipidemia
- fatty liver sleep aspiration syndrome
- obesity hypoventilation syndrome orthopedic disease (lumbar spondylosis, deformed knee)
- arthritis osteospin formation, etc.
- menstrual abnormalities pregnancy complications (pregnancy hypertension syndrome, obesity, etc.), and diseases related to any of these.
- the content of prenylflavonoid in the present embodiment with respect to the total amount of the above-mentioned drug is not particularly limited as long as the action / effect of the prenylflavonoid in the present embodiment is exhibited, but the total amount of prenylflavonoid in the present embodiment is preferable in one embodiment. It is 0.00001% by mass or more, 0.00005% by mass or more in another preferable aspect, 0.0001% by mass or more in yet another preferable aspect, and 5% by mass or less in another preferable aspect. In another preferred embodiment, it is 0.5% by mass or less, and in yet another preferred embodiment, it is 0.05% by mass or less.
- the effective dose of the above-mentioned drug is appropriately set depending on the age, body weight, disease, etc., degree, administration route, administration schedule, formulation form, etc. of the subject, and by administering it to a mammal, the mammal can be treated. It is not particularly limited as long as the action / effect of the prenylflavonoid of this embodiment is exhibited.
- the total amount of prenylflavonoids in this embodiment is 0.01 mg or more per day and kg body weight in one preferred embodiment, 0.05 mg or more in another preferred embodiment, and 0. It is 1 mg or more, 1000 mg or less in one preferred embodiment, 100 mg or less in another preferred embodiment, and 10 mg or less in yet another preferred embodiment.
- the above-mentioned medicine may be administered once a day or may be administered in a plurality of times a day. It may also be administered once every few days or weeks.
- prenylflavonoid of the present embodiment is used as a material for foods and drinks, in addition to general foods and drinks, foods for specified health use, dietary supplements, functional foods, foods for the sick, food additives, etc. Included.) Can be used.
- the form of the food or drink may be a form other than the plant itself or the animal itself containing the prenylflavonoid of the present embodiment.
- a form suitable for edible use is used by conventional means. For example, it may be formed into granules, granules, tablets, capsules, pastes, etc.
- processed meat foods such as ham and sausage
- processed marine foods such as kamaboko and chikuwa
- It may be added to bread, confectionery, butter, milk powder, fermented dairy products, or added to beverages such as water, fruit juice, milk, and soft drinks.
- the above foods and drinks can be mainly composed of water, proteins, sugars, lipids, vitamins, minerals, organic acids, organic bases, fruit juices, flavors and the like.
- the protein include animal and vegetable proteins such as full-fat milk powder, skim milk powder, partially skim milk powder, casein, soybean protein, chicken egg protein, meat protein, and hydrolyzates and butters thereof.
- sugars include sugars, modified starches (in addition to dextrin, soluble starches, British starch, oxidized starches, starch esters, starch ethers, etc.), dietary fiber and the like.
- Examples of the lipid include lard, safflower oil, corn oil, rapeseed oil, coconut oil, fractionated oils thereof, hydrogenated oil, and vegetable fats and oils such as ester exchange oil.
- vitamins include vitamin A, carotene, vitamin B group, vitamin C, vitamin D group, vitamin E, vitamin K group, vitamin P, vitamin Q, niacin, nicotinic acid, pantothenic acid, biotin, inositol, and choline.
- Folic acid and the like, and examples of minerals include calcium, potassium, magnesium, sodium, copper, iron, manganese, zinc, selenium and milky minerals.
- Examples of the organic acid include malic acid, citric acid, lactic acid, tartaric acid and the like. As these components, two or more kinds may be used in combination, and synthetic products and / or foods and drinks containing a large amount thereof may be used.
- the above food and drink can be manufactured according to a conventional method.
- the blending amount, blending method, and blending time of prenylflavonoid in the food and drink of the present embodiment can be appropriately selected. Further, if necessary, it can be sealed in an appropriate container such as a bottle, a bag, a can, a box, or a pack.
- the content of prenylflavonoid in the present embodiment with respect to the total amount of the food and drink is not particularly limited as long as the action / effect of the prenylflavonoid in the present embodiment is exhibited, but it is a preferable aspect as the total amount of prenylflavonoid in the present embodiment.
- it is 0.00001% by mass or more, in yet another preferred embodiment, it is 0.0001% by mass or more, and in another preferred embodiment, it is 5% by mass or more. In another preferred embodiment, it is 0.5% by mass or less, and in yet another preferred embodiment, it is 0.05% by mass or less.
- the effective intake of the food and drink is appropriately set according to the age, body weight, intake route, intake schedule, form, etc. of the subject, and by ingesting it in a mammal, the prenylflavonoid of the present embodiment is produced in the mammal.
- the total amount of prenylflavonoids in this embodiment is 0.01 mg or more per day and kg body weight in one preferred embodiment, 0.05 mg or more in another preferred embodiment, and 0. It is 1 mg or more, 1000 mg or less in one preferred embodiment, 100 mg or less in another preferred embodiment, and 10 mg or less in yet another preferred embodiment.
- the above-mentioned food and drink may be ingested once a day or may be ingested in a plurality of times a day. It may also be taken once every few days or weeks.
- the prenylflavonoid of this embodiment can be used as a feed material.
- the feed raw material and the prenylflavonoid of the present embodiment may be appropriately blended according to the breeding environment such as the type of mammal, the development stage, and the area.
- feed raw materials include cereals or processed grains (corn, mylo, barley, etc.), bran (bran, rice bran, corn gluten feed, etc.), vegetable oil cake (soybean oil cake, sesame oil cake, cottonseed oil cake, etc.).
- Animal raw materials defatted milk powder, fish flour, meat bone powder, etc.
- minerals calcium carbonate, calcium phosphate, salt, silicic anhydride, etc.
- vitamins amino acids
- yeasts such as beer yeast
- fine powder of inorganic substances Crystalline cellulose, corn, silica, etc.
- the feed is a feed additive such as excipients, bulking agents, binders, thickeners, emulsifiers, colorants, fragrances, food additives, and seasonings that are usually used in compound feeds.
- feed additive such as excipients, bulking agents, binders, thickeners, emulsifiers, colorants, fragrances, food additives, and seasonings that are usually used in compound feeds.
- other ingredients antioxidants, bactericides, insecticides, preservatives, etc. may be blended if desired.
- the form of the feed is not particularly limited, and examples thereof include powder, granule, paste, pellet, capsule (hard capsule, soft capsule), tablet, etc., and pet food for pet animals and experiments. It may be used as a feed for animals.
- the content of prenylflavonoid in the present embodiment with respect to the total amount of the feed is not particularly limited as long as the action / effect of the prenylflavonoid in the present embodiment is exhibited, but the total amount of prenylflavonoid in the present embodiment is preferable in one embodiment. It is 0.00001% by mass or more, 0.00005% by mass or more in another preferable aspect, 0.0001% by mass or more in yet another preferable aspect, and 5% by mass or less in another preferable aspect. In another preferred embodiment, it is 0.5% by mass or less, and in yet another preferred embodiment, it is 0.05% by mass or less.
- the effective dose of the feed is appropriately set according to the age, body weight, administration route, administration schedule, formulation form, etc. of the subject, and by administering it to a mammal, the prenylflavonoid of the present embodiment can be administered to the mammal.
- the total amount of prenylflavonoids in this embodiment is 0.01 mg or more per day and kg body weight in one preferred embodiment, 0.05 mg or more in another preferred embodiment, and 0. It is 1 mg or more, 1000 mg or less in one preferred embodiment, 100 mg or less in another preferred embodiment, and 10 mg or less in yet another preferred embodiment.
- the feed may be administered once a day or may be administered in a plurality of times a day. It may also be administered once every few days or weeks.
- the present specification can also provide the following embodiments. For the details, the contents described above are used.
- the prenylflavonoid of the present embodiment for use in the prevention or amelioration of diseases and the like that can be prevented or ameliorated by the prenylflavonoid of the present embodiment.
- a method for preventing a disease or the like that can be prevented or ameliorated by the prenylflavonoid of the present embodiment which comprises administering a prophylactically or ameliorating effective amount of the prenylflavonoid of the present embodiment to a mammal in need of prevention or improvement. How to improve.
- Example 1 C57BL / 6 male mice (Nippon SLC) were divided into the following 4 groups of 6 mice in each group.
- 8-prenylnaringenin (may be referred to as 8PN in the present specification) was used.
- Group 1 Group to ingest a normal diet without 8PN (Group 2) Group to ingest a normal diet with 8PN added (final concentration: 0.0005%) (Group 3) Normal diet with 8PN added (final concentration: 0.005%) Group (Group 4) Group to ingest a high-fat diet without 8PN (Group 5) Group to ingest a high-fat diet with 8PN (final concentration: 0.0005%) (Group 6) Add 8PN (Final concentration:)
- a group ingesting a high-fat diet of 0.005%) AIN-93M diet was used for the normal diet (control diet), and AIN-93M diet containing 30% lard was used for the high-fat diet. In groups 2, group 3, group 5 and group 6, these were mixed with 8PN.
- mice were bred in individual cages, fed with free intake of each feed and deionized water, and bred for 8 weeks.
- the breeding environment was 22 ⁇ 2 ° C., the humidity changed, and the light-dark cycle was performed every 12 hours.
- the mice were sacrificed by cardiac blood sampling under co-anesthesia of sevofran and somnopentyl, and then weighed and weighed. Then, subcutaneous adipose tissue, brown adipose tissue, mesenteric adipose tissue, perineal adipose tissue, and supraclavicular adipose tissue were excised from the mouse, and the fat weight in each tissue was weighed and measured. Further, from the extracted fat, the total weight of adipose tissue other than brown adipose tissue was calculated as the weight of white adipose tissue.
- FIGS. 1 to 7 show the weight at the end of the test, the fat weight of subcutaneous adipose tissue, the fat weight of brown adipose tissue, the fat weight of mesenteric adipose tissue, the fat weight of perirenal adipose tissue, and the testis, respectively.
- the fat weight of upper body adipose tissue and the fat weight of white adipose tissue are shown.
- Example 2 Up to the slaughter of Example 1, the same procedure as in Example 1 was carried out. At the time of the sacrifice, blood was collected from the mouse and centrifuged at 5000 rpm for 10 minutes to obtain plasma from the supernatant. Glucose CII test Wako (Fujifilm Wako Pure Chemical Industries, Ltd.) was used to measure the amount of glucose, and Levis (registered trademark) insulin-mouse (RTU) (Fujifilm Wako Pure Chemical Industries, Ltd.) was used to measure the amount of insulin. .. In addition, the amount of cholesterol was measured using laboratory assay cholesterol (Fujifilm Wako Pure Chemical Industries, Ltd.).
- Example 3 Up to the slaughter of Example 1, the same procedure as in Example 1 was carried out. At the time of the sacrifice, the thigh muscles were removed from the mice, and the weight of each muscle was weighed and measured.
- FIG. 11 shows the weight of the thigh muscle.
- groups 5 and 6 the weight of the thigh muscles was increased as compared with group 4 (* indicates p ⁇ 0.05 in the figure).
- the weight of the thigh muscle was also increased in the groups 2 and 3 in which the normal diet was ingested as compared with the group 1 (* indicates p ⁇ 0.05 in the figure).
- Example 4 An enzyme solution was prepared by dissolving porcine-derived pancreatic lipase II (manufactured by Sigma) in 100 mM Tris-HCl buffer (pH 7.0) so that the final concentration was 250 ⁇ g / mL. In addition, 80 mg trioleic acid, 10 mg lecithin, and 5 mg sodium cholate were dissolved in 9 mL of 100 mM Tris-HCl buffer (pH 7.0), sonicated for 10 minutes, and the substrate was a uniform suspension. The solution was prepared.
- a test reaction solution having a total volume of 0.1 mL was prepared, and an enzymatic reaction was carried out at 37 ° C. for 30 minutes. The reaction was stopped by heat treatment at 100 ° C. for 2 minutes, and the amount of free fatty acid was measured with absorbance at a wavelength of 550 nm using NEFA C-Test Wako (Fujifilm Wako Pure Chemical Industries, Ltd.). The larger the amount of free fatty acid, the greater the lipase activity.
- the control was the same as above except that DMSO was used instead of 8PN. In addition, the same as above was used as a blank except that the enzyme solution was not added.
- Fig. 12 shows the relationship between the 8PN concentration and the lipase activity inhibition rate.
- the lipase activity inhibition rate increased in a concentration-dependent manner of 8PN.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Diabetes (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Nutrition Science (AREA)
- Child & Adolescent Psychology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Emergency Medicine (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurology (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
〔2〕前記プレニルフラボノイドが8-プレニルナリンゲニンである、〔1〕に記載の組成物。
〔3〕前記肥満抑制が、体重増加抑制又は体脂肪増加抑制である、〔1〕又は〔2〕に記載の組成物。
〔4〕前記肥満抑制が、内臓脂肪増加抑制又は皮下脂肪増加抑制である、〔1〕~〔3〕のいずれかに記載の組成物。
〔5〕前記肥満抑制が、肝臓、腸間膜、腎周囲又は精巣上体の内臓脂肪の増加抑制である、〔1〕~〔4〕のいずれかに記載の組成物。
〔6〕白色脂肪の増加抑制に用いられる、〔1〕~〔5〕のいずれかに記載の組成物。
〔7〕膵リパーゼの活性阻害に用いられる、〔1〕~〔6〕のいずれかに記載の組成物。
〔8〕グルコース、コレステロール、又はインスリンの血中濃度の上昇抑制に用いられる、〔1〕~〔7〕のいずれかに記載の組成物。
〔9〕筋肉重量の増加に用いられる、〔1〕~〔8〕のいずれかに記載の組成物。
〔10〕前記筋肉が大腿筋である、〔9〕に記載の組成物。
〔11〕医薬である、〔1〕~〔10〕のいずれかに記載の組成物。
〔12〕飲食品である、〔1〕~〔10〕のいずれかに記載の組成物。
プレニルケルセチンとしては8-プレニルケルセチン、6-プレニルケルセチン、5’-プレニルケルセチンが例示できる。
プレニルエリオジクチオールとしては、ニムフェオールA、ニムフェオールB、ニムフェオールC、イソニムフェオールCが例示できる。
プレニルゲニステインとしては6-プレニルゲニステインが例示できる。
尚、キサントフモールは、上記一般式(1)で表される構造を有していない。
また、本実施態様の組成物は、1日あたり1回の摂取又は投与でもよいし、1日に複数回に分けた摂取又は投与でもよい。また、数日又は数週間に1回の摂取又は投与であってもよい。
本明細書における肥満抑制作用が体重増加抑制作用であるときは、哺乳動物が本実施態様のプレニルフラボノイドを摂取した又は投与されたときに、摂取しない又は投与されないときよりも、該哺乳動物の体重を小さい状態にすること又は同等の状態にすることをいう。体重は、例えば、体重計で測定することができる。
本明細書における肥満抑制作用が体脂肪増加抑制作用であるときは、哺乳動物が本実施態様のプレニルフラボノイドを摂取した又は投与されたときに、摂取しない又は投与されないときよりも、該哺乳動物の体脂肪を少ない状態にすること又は同等の状態にすることをいう。体脂肪は、例えば、体内から摘出した脂肪組織の秤量、インピーダンス法による体脂肪率の計測、CTスキャン撮影後の脂肪面積の計測などを通じて測定することができる。
内臓脂肪は、上記測定法のほか、例えば、体内の各臓器周囲に付着した脂肪組織を摘出して秤量し、その総和を計測することにより測定することもできる。また、皮下脂肪は、上記測定法のほか、例えば、毛皮下組織から摘出した脂肪組織を秤量することにより測定することもできる。
いずれの内臓脂肪も、上記測定法のほか、例えば、当該組織の周囲に沈着した脂肪組織を摘出して秤量することにより測定することもできる。
このことから、本明細書にて、本実施態様のプレニルフラボノイドを有効成分として含む、白色脂肪増加抑制用組成物を提供することができる。また、本明細書にて、本実施態様のプレニルフラボノイドを有効成分として含む、白色脂肪の増加抑制に用いられる肥満抑制用組成物を提供することができる。
白色脂肪の増加抑制作用とは、哺乳動物が本実施態様のプレニルフラボノイドを摂取した又は投与されたときに、摂取しない又は投与されないときよりも、該哺乳動物の白色脂肪を少ない状態にすること又は同等の状態にすることをいう。白色脂肪は、例えば、体内から摘出した白色脂肪組織の秤量、インピーダンス法による計測、CTスキャン撮影後の脂肪面積の計測などを通じて測定することができる。
また、in vitro系においては、例えば、白色脂肪細胞内に発現する白色脂肪細胞分化マーカーをウエスタンブロッティングにて測定することにより測定することができる。該白色脂肪細胞としては、マウス線維芽細胞3T3-L1に由来する細胞が例示できる。
このことから、本明細書にて、本実施態様のプレニルフラボノイドを有効成分として含む、膵リパーゼ活性阻害用組成物を提供することができる。また、本明細書にて、本実施態様のプレニルフラボノイドを有効成分として含む、膵リパーゼの活性阻害に用いられる肥満抑制用組成物を提供することができる。
膵リパーゼの活性阻害作用とは、哺乳動物が本実施態様のプレニルフラボノイドを摂取した又は投与されたときに、摂取しない又は投与されないときよりも、該哺乳動物の膵リパーゼの活性阻害が大きいことをいう。
膵リパーゼの活性阻害の程度は、in vitro系においては、例えば活性阻害率で評価することができ、活性阻害率は、例えば後述する実施例のようにして算出することができる。また、例えば、トリアシルグリセロールのエステル結合を加水分解し、脂肪酸とグリセリンへ分解する作用を有する酵素の活性を阻害又は抑制する作用を評価することができればよく、例えば、4-メチルウンベリフェロンの脂肪酸エステルを基質として用い、ブタ膵臓由来のリパーゼを作用させ、酵素反応後に遊離した4-メチルウンベリフェロンを蛍光測定法によって定量することにより測定することができる。
このことから、本明細書にて、本実施態様のプレニルフラボノイドを有効成分として含む、腸管での脂肪吸収を抑制するための組成物を提供することができる。また、本明細書にて、本実施態様のプレニルフラボノイドを有効成分として含む、腸管での脂肪吸収の抑制に用いられる肥満抑制用組成物を提供することができる。
このことから、本明細書にて、本実施態様のプレニルフラボノイドを有効成分として含む、グルコース、コレステロール、又はインスリンの血中濃度の上昇を抑制するための組成物を提供することができる。また、本明細書にて、本実施態様のプレニルフラボノイドを有効成分として含む、グルコース、コレステロール、又はインスリンの血中濃度の上昇抑制に用いられる肥満抑制用組成物を提供することができる。
グルコース、コレステロール、又はインスリンの血中濃度の上昇抑制作用とは、哺乳動物が本実施態様のプレニルフラボノイドを摂取した又は投与されたときに、摂取しない又は投与されないときよりも、該哺乳動物のグルコース、コレステロール、又はインスリンの血中濃度が小さい状態にすること又は同等の状態にすることをいう。
いずれの血中濃度も、例えば、市販されている測定キットを用いて測定することができる。
このことから、本明細書にて、本実施態様のプレニルフラボノイドを有効成分として含む、筋肉重量増加用組成物を提供することができる。また、本明細書にて、本実施態様のプレニルフラボノイドを有効成分として含む、筋肉重量の増加に用いられる肥満抑制用組成物を提供することができる。
筋肉重量の増加作用とは、哺乳動物が本実施態様のプレニルフラボノイドを摂取した又は投与されたときに、摂取しない又は投与されないときよりも、該哺乳動物の筋肉重量が大きいことをいう。筋肉重量は、例えば、体成分分析測定やDual Energy X-ray Absorptiometry(DXA)法による測定のほか、体内から筋肉を摘出後、天秤などで秤量して測定することもできる。
前記筋肉としては、大腿筋が例示できる。
大腿筋の重量は、上記測定法のほか、例えば、体内から摘出後、天秤などで秤量して測定することができる。
このことから、本明細書にて、本実施態様のプレニルフラボノイドを有効成分として含む、体外への体脂肪の排出を促進するための組成物を提供することができる。また、本明細書にて、本実施態様のプレニルフラボノイドを有効成分として含む、体外への体脂肪の排出促進に用いられる肥満抑制用組成物を提供することができる。
体外への体脂肪の排出を促進する作用とは、哺乳動物が本実施態様のプレニルフラボノイドを摂取した又は投与されたときに、摂取しない又は投与されないときよりも、該哺乳動物の体外へ排出される体脂肪量が多いことをいう。体外へ排出される体脂肪量は、例えば、Folch法を用いて糞中に排泄された脂質を抽出し秤量して測定することができる。
このことから、本明細書にて、本実施態様のプレニルフラボノイドを有効成分として含む、脂肪酸のβ酸化酵素を活性化するための組成物を提供することができる。また、本明細書にて、本実施態様のプレニルフラボノイドを有効成分として含む、脂肪酸のβ酸化酵素の活性化に用いられる肥満抑制用組成物を提供することができる。
脂肪酸のβ酸化酵素を活性化する作用とは、哺乳動物が本実施態様のプレニルフラボノイドを摂取した又は投与されたときに、摂取しない又は投与されないときよりも、脂肪酸のβ酸化酵素の活性が高いことをいう。脂肪酸のβ酸化酵素の活性は、例えば、β酸化酵素のmRNA量を測定し、遺伝子発現量を確認することにより測定することができる。
また、上記医薬は、1日あたり1回の投与でもよいし、1日に複数回に分けた投与でもよい。また、数日又は数週間に1回の投与であってもよい。
また、上記飲食品は、1日あたり1回の摂取でもよいし、1日に複数回に分けた摂取でもよい。また、数日又は数週間に1回の摂取であってもよい。
飼料原料としては、例えば、穀物類または加工穀物類(とうもろこし、マイロ、大麦等)、糟糠類(ふすま、米糠、コーングルテンフィード等)、植物性油粕類(大豆油粕、ごま油粕、綿実油粕等)、動物性原料(脱脂粉乳、魚粉、肉骨粉等)、ミネラル類(炭酸カルシウム、リン酸カルシウム、食塩、無水ケイ酸等)、ビタミン類、アミノ酸類、ビール酵母などの酵母類、無機物質の微粉末(結晶性セルロース、タルク、シリカ等)などが挙げられる。
また、上記飼料は、1日あたり1回の投与でもよいし、1日に複数回に分けた投与でもよい。また、数日又は数週間に1回の投与であってもよい。
肥満抑制用組成物を製造するための本実施態様のプレニルフラボノイドの使用。
本実施態様のプレニルフラボノイドによって予防又は改善され得る疾患等の予防又は改善における使用のための本実施態様のプレニルフラボノイド。
肥満抑制のための、本実施態様のプレニルフラボノイドの使用。
本実施態様のプレニルフラボノイドの予防的又は改善的有効量を、予防又は改善を必要とする哺乳動物に投与することを含む、本実施態様のプレニルフラボノイドによって予防又は改善され得る疾患等の予防方法又は改善方法。
C57BL/6雄性マウス(日本エスエルシー)を各群6匹の下記4群に分けた。尚、本実施態様のプレニルフラボノイドとして8-プレニルナリンゲニン(本明細書では、8PNと記載することがある。)を用いた。
(群1)8PN非添加の普通食を摂取させる群
(群2)8PN添加(終濃度:0.0005%)の普通食を摂取させる群
(群3)8PN添加(終濃度:0.005%)の普通食を摂取させる群
(群4)8PN非添加の高脂肪食を摂取させる群
(群5)8PN添加(終濃度:0.0005%)の高脂肪食を摂取させる群
(群6)8PN添加(終濃度:0.005%)の高脂肪食を摂取させる群
普通食(コントロール食)にはAIN-93M飼料を用い、高脂肪食には30%ラードを含むAIN-93M飼料を用いた。群2、群3、群5及び群6ではこれらに8PNを混餌した。
マウスはそれぞれ個別ケージで飼育し、各飼料および脱イオン水を自由摂取させ、8週間飼育した。飼育環境は、22±2℃、湿度成り行き、12時間ごとの明暗サイクルで行った。8週間後、セボフランとソムノペンチルの共麻酔下での心採血によりマウスを屠殺した後、秤量して体重を測定した。その後、皮下脂肪組織、褐色脂肪組織、腸間膜脂肪組織、腎周囲脂肪組織、及び精巣上体脂肪組織をマウスから摘出し、各組織中の脂肪重量を天秤により秤量して測定した。また、摘出した脂肪から、褐色脂肪組織以外の脂肪組織の総重量を白色脂肪組織の重量として算出した。
群5及び群6では、群4に比べて、体重の増加、皮下脂肪組織の脂肪重量の増加、褐色脂肪組織の脂肪重量の増加、腸間膜脂肪組織の脂肪重量の増加、腎周囲脂肪組織の脂肪重量の増加、精巣上体脂肪組織の脂肪重量、白色脂肪組織の脂肪重量の増加が抑制された(図中、*はp < 0.05を示す。)。
実施例1の屠殺までは実施例1と同様に行った。該屠殺時にマウスから採血をし、5000rpm、10分間の遠心分離をしてその上清から血漿を得た。グルコースCIIテストワコー(富士フイルム和光純薬株式会社)を用いてグルコース量を測定し、レビス(登録商標)インスリン-マウス(RTU)(富士フイルム和光純薬株式会社)を用いてインスリン量を測定した。また、ラボアッセイコレステロール(富士フイルム和光純薬株式会社)を用いてコレステロール量を測定した。
群5及び群6では、群4に比べて、グルコース、コレステロール及びインスリンの血中濃度の上昇が抑制された。
実施例1の屠殺までは実施例1と同様に行った。該屠殺時にマウスから大腿筋を摘出し、各筋肉の重量を天秤で秤量して測定した。
群5及び群6では、群4に比べて、大腿筋の重量が増加した(図中、*はp < 0.05を示す。)。尚、普通食を摂取させる群である群2及び群3でも、群1に比べて、大腿筋の重量が増加した(図中、*はp < 0.05を示す。)。
終濃度が250μg/mLとなるように、ブタ由来の膵リパーゼII(Sigma社製)を100mM Tris-HCl緩衝液(pH7.0)に溶解して酵素液を調製した。また、80mgトリオレイン酸、10mgレシチン、5mgコール酸ナトリウムを、9mLの100mM Tris-HCl緩衝液(pH7.0)に溶解し、10分間の超音波処理をし、均一な懸濁液である基質溶液を調製した。0.04mLの該基質溶液、0.04mLの8PN溶液(終濃度: 1.0 mg/mL、2.0 mg/mL、4.0 mg/mL、7.0 mg/mL又は10.0 mg/mL)、0.02mLの前記酵素液からなる全量0.1mLの試験反応液を調製し、37℃、30分間の酵素反応を行った。100℃、2分間の加熱処理によって反応を停止させ、NEFA C-テストワコー(富士フイルム和光純薬株式会社)を用い、波長550nmにおける吸光度をもって遊離脂肪酸量を測定した。尚、遊離脂肪酸量が大きいほどリパーゼ活性が大きい。
リパーゼ活性阻害率(%)={1-((B-A)/(C-A))}×100 ・・・(1)
A:ブランクの吸光度
B:試験反応液の吸光度
C:コントロールの吸光度
Claims (12)
- 前記プレニルフラボノイドが8-プレニルナリンゲニンである、請求項1に記載の組成物。
- 前記肥満抑制が、体重増加抑制又は体脂肪増加抑制である、請求項1又は2に記載の組成物。
- 前記肥満抑制が、内臓脂肪増加抑制又は皮下脂肪増加抑制である、請求項1~3のいずれか一項に記載の組成物。
- 前記肥満抑制が、肝臓、腸間膜、腎周囲又は精巣上体の内臓脂肪の増加抑制である、請求項1~4のいずれか一項に記載の組成物。
- 白色脂肪の増加抑制に用いられる、請求項1~5のいずれか一項に記載の組成物。
- 膵リパーゼの活性阻害に用いられる、請求項1~6のいずれか一項に記載の組成物。
- グルコース、コレステロール、又はインスリンの血中濃度の上昇抑制に用いられる、請求項1~7のいずれか一項に記載の組成物。
- 筋肉重量の増加に用いられる、請求項1~8のいずれか一項に記載の組成物。
- 前記筋肉が大腿筋である、請求項9に記載の組成物。
- 医薬である、請求項1~10のいずれか一項に記載の組成物。
- 飲食品である、請求項1~10のいずれか一項に記載の組成物。
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202080087340.6A CN115038435A (zh) | 2019-12-20 | 2020-12-18 | 肥胖抑制用组合物 |
JP2021565691A JPWO2021125342A1 (ja) | 2019-12-20 | 2020-12-18 | |
US17/757,610 US20230040395A1 (en) | 2019-12-20 | 2020-12-18 | Composition for suppressing obesity |
EP20903123.6A EP4079302A4 (en) | 2019-12-20 | 2020-12-18 | COMPOSITION FOR SUPPRESSING OBESITY |
KR1020227024761A KR20220118504A (ko) | 2019-12-20 | 2020-12-18 | 비만 억제용 조성물 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2019-230188 | 2019-12-20 | ||
JP2019230188 | 2019-12-20 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2021125342A1 true WO2021125342A1 (ja) | 2021-06-24 |
Family
ID=76477384
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2020/047516 WO2021125342A1 (ja) | 2019-12-20 | 2020-12-18 | 肥満抑制用組成物 |
Country Status (6)
Country | Link |
---|---|
US (1) | US20230040395A1 (ja) |
EP (1) | EP4079302A4 (ja) |
JP (1) | JPWO2021125342A1 (ja) |
KR (1) | KR20220118504A (ja) |
CN (1) | CN115038435A (ja) |
WO (1) | WO2021125342A1 (ja) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20240033981A (ko) | 2022-09-06 | 2024-03-13 | 국립낙동강생물자원관 | 회화나무 추출물을 유효성분으로 포함하는 비만의 예방 및 개선용 조성물 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2005526122A (ja) | 2002-05-10 | 2005-09-02 | シエーリング アクチエンゲゼルシャフト | 抗血管新生療法のためのならびに繊維素溶解療法のための8−プレニルフラバノンの使用 |
JP2009518429A (ja) * | 2005-12-09 | 2009-05-07 | メタプロテオミクス,エルエルシー | 代謝症候群および糖尿病の治療のための抗炎症植物産物 |
JP2012193157A (ja) * | 2011-03-03 | 2012-10-11 | Kaneka Corp | 筋肉増量剤 |
JP2016136952A (ja) | 2016-02-05 | 2016-08-04 | ポッカサッポロフード&ビバレッジ株式会社 | 廃用性筋萎縮抑制用剤、廃用性筋萎縮抑制用飲食品組成物、及び廃用性筋萎縮抑制用飲食品組成物の製造方法 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2401361B1 (es) * | 2011-06-16 | 2014-01-22 | Universidad Autónoma de Madrid | Bebida funcional cardiosaludable de vino y extractos de lúpulo |
JP7058225B2 (ja) * | 2016-12-20 | 2022-04-21 | サントリーホールディングス株式会社 | イソキサントフモールを含む脂質代謝促進用組成物 |
WO2018150499A1 (ja) * | 2017-02-15 | 2018-08-23 | サントリーホールディングス株式会社 | 容器詰発酵飲料およびその製造方法 |
-
2020
- 2020-12-18 US US17/757,610 patent/US20230040395A1/en active Pending
- 2020-12-18 WO PCT/JP2020/047516 patent/WO2021125342A1/ja unknown
- 2020-12-18 CN CN202080087340.6A patent/CN115038435A/zh active Pending
- 2020-12-18 JP JP2021565691A patent/JPWO2021125342A1/ja active Pending
- 2020-12-18 KR KR1020227024761A patent/KR20220118504A/ko unknown
- 2020-12-18 EP EP20903123.6A patent/EP4079302A4/en active Pending
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2005526122A (ja) | 2002-05-10 | 2005-09-02 | シエーリング アクチエンゲゼルシャフト | 抗血管新生療法のためのならびに繊維素溶解療法のための8−プレニルフラバノンの使用 |
JP2009518429A (ja) * | 2005-12-09 | 2009-05-07 | メタプロテオミクス,エルエルシー | 代謝症候群および糖尿病の治療のための抗炎症植物産物 |
JP2012193157A (ja) * | 2011-03-03 | 2012-10-11 | Kaneka Corp | 筋肉増量剤 |
JP2016136952A (ja) | 2016-02-05 | 2016-08-04 | ポッカサッポロフード&ビバレッジ株式会社 | 廃用性筋萎縮抑制用剤、廃用性筋萎縮抑制用飲食品組成物、及び廃用性筋萎縮抑制用飲食品組成物の製造方法 |
Non-Patent Citations (6)
Title |
---|
CHANG, CHIHLING ET AL.: "Antiobesity effect of brewer's yeast biomass in animal model", JOURNAL OF FUNCTIONAL FOOD S, vol. 55, April 2019 (2019-04-01), pages 255 - 262, XP085637507, DOI: 10.1016/j.jff.2019.02.027 * |
COSTA RAQUEL, RODRIGUES ILDA, GUARDÃO LUÍSA, ROCHA-RODRIGUES SÍLVIA, SILVA CAROLINA, MAGALHÃES JOSÉ, FERREIRA-DE-ALMEIDA MANUEL, N: "Xanthohumol and 8- prenylnaringenin ameliorate diabetic-related metabolic dysfunctions in mice", JOURNAL OF NUTRITIONAL BIOCHEMISTRY, vol. 45, 2017, pages 39 - 47, XP055836616 * |
HAYASHI HIROAKI , SHUI-LI ZHANG, TOMOKO NAKAIZUMI, KUMIKO SHIMURA, MISAKO YAMAGUCHI, KENICHIRO INOUE, KANAT SARSENBAEV, MICHIHO IT: "Field Survey of Glycyrrhiza Plants in Central Asia (2). Characterization of Phenolics and Their Variation in the Leaves of Glycyrrhiza Plants Collected in Kazakhstan", CHEM. PHARM. BULL., vol. 51, no. 10, 2003, pages 1147 - 1152, XP055836618 * |
JO YANG HEE; KIM SEON BEOM; LIU QING; LEE JIN WOO; HWANG BANG YEON; LEE MI KYEONG: "Benzylated and prenylated flavonoids from the root barks of Cudrania tricuspidata with pancreatic lipase inhibitory activity", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, vol. 25, 2015, pages 3455 - 3457, XP029249484 * |
MUKAI, RIE ET AL.: "Prevention of Disuse Muscle Atrophy by Dietary Ingestion of 8-Prenylnaringenin in Denervated Mice", PLOS ONE, vol. 7, no. 9, 2012, pages 1 - 11, XP055584502 * |
See also references of EP4079302A4 |
Also Published As
Publication number | Publication date |
---|---|
KR20220118504A (ko) | 2022-08-25 |
CN115038435A (zh) | 2022-09-09 |
EP4079302A4 (en) | 2023-12-20 |
US20230040395A1 (en) | 2023-02-09 |
EP4079302A1 (en) | 2022-10-26 |
JPWO2021125342A1 (ja) | 2021-06-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR101262686B1 (ko) | 체지방 감소용 조성물 | |
CN110023487B (zh) | 新型清酒乳杆菌和包含其的组合物 | |
WO2011077800A1 (ja) | 高脂血症改善剤、並びに、貧血改善組成物、尿酸値低下組成物及び飲食品 | |
WO2020009111A1 (ja) | 脂肪蓄積抑制用組成物 | |
TWI389697B (zh) | Improve the composition of lipid metabolism | |
WO2006033355A1 (ja) | 皮膚の乾燥予防または改善用経口剤 | |
JPWO2009142320A1 (ja) | アトピー性皮膚炎予防剤及び/または治療剤 | |
WO2021125342A1 (ja) | 肥満抑制用組成物 | |
EP1090635B1 (en) | Use of ferulic acid for treating hypertension | |
US20060189566A1 (en) | Muscle building agent and preventive or remedy for muscle weakening | |
JP4401659B2 (ja) | インスリン分泌促進剤 | |
JP2009269832A (ja) | カルシトニン遺伝子関連ペプチド及びインスリン様成長因子−1の産生促進組成物 | |
KR20210020988A (ko) | 잔소리졸을 유효성분으로 함유하는 골형성 촉진용 조성물 | |
EP2999467B1 (fr) | Utilisation d'une association de deux composés pour le traitement et/ou la prévention de troubles osseux | |
EP1327443A1 (en) | Therapeutic or preventing agent for the diseases caused by a decrease in the expression level of the klotho protein | |
WO2007034958A1 (ja) | 穀類由来の成分を有効成分とする血管新生阻害の作用を有する組成物 | |
JP2011012005A (ja) | 高脂血症改善剤 | |
KR101354314B1 (ko) | 공액리놀레산을 함유하는 키토산 코팅된 나노 리포좀 및 이의 제조방법 | |
JP2007039386A (ja) | マーカータンパク質量調節用組成物、及びそれを含有する飲食品、飼料、医薬部外品、医薬品 | |
JP6131275B2 (ja) | Igf−1産生促進剤 | |
JPWO2008111651A1 (ja) | メタボリックシンドローム改善又は予防剤、並びにこれを含有する飲料、食品及び飼料 | |
WO2022050308A1 (ja) | Nampt遺伝子発現増強用組成物 | |
JP2010105948A (ja) | 脂肪肝抑制剤 | |
JP5215858B2 (ja) | 抗血管新生作用を有する抽出物とレシチンを含有する抗血管新生組成物 | |
JP2978581B2 (ja) | コレステロール抑制剤 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 20903123 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2021565691 Country of ref document: JP Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 20227024761 Country of ref document: KR Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2020903123 Country of ref document: EP Effective date: 20220720 |